FOSUN HEALTH Logo

Autoimmune Encephalitis Treatment

catalogue

Autoimmune Encephalitis Treatment

Autoimmune Encephalitis Treatment

Treatment for autoimmune encephalitis has an order, and the order is the treatment. Two things happen before any result is available, one thing happens only if a tumour is found, two lines of immunotherapy exist and are used in sequence rather than together, and the part that lasts longest is not immunosuppression at all but rehabilitation. This page sets out what is given, in what order, what each step is for, what it costs the person in side effects and monitoring, and — because this is the question families actually ask — how long the recovery takes and what the rest of it looks like.

The order treatment is given in

Ask ten people what the treatment for this illness is and you will get ten different answers, usually naming a drug. The useful answer is a sequence, because the sequence is where the mistakes happen — and the mistakes are almost always about timing rather than about choice of agent.

Step What When What it is for
1. Aciclovir Intravenous antiviral, usually continued until infection is excluded On suspicion — while the cerebrospinal fluid results are awaited, not after To cover herpes simplex encephalitis, which is the one alternative that must not be missed and is treated before it is confirmed
2. First-line immunotherapy High-dose corticosteroid, intravenous immunoglobulin, plasma exchange — alone or in combination Once the criteria are met, without waiting for the antibody panel To interrupt the immune attack during the window in which doing so changes the outcome
3. Tumour removal Surgical removal of the driving tumour, where one is found As soon as it is found and the person is fit enough; not deferred to the end of immunotherapy To remove the source of the immune stimulus. In paraneoplastic cases this is the step most likely to change the course
4. Second-line immunotherapy Rituximab, or cyclophosphamide in selected cases After a documented inadequate response to first-line treatment, usually days to weeks in To suppress the antibody-producing cells that first-line treatment does not reach
5. Supportive and intensive care Seizure control, ventilatory support, autonomic management, swallowing and nutrition, clot prevention Throughout, escalating and de-escalating with the illness To carry the person through the severe phase while the immunotherapy takes effect. This is not comfort care; it is the treatment
6. Maintenance and taper Ongoing immunosuppression at a lower intensity, reduced slowly with defined review points After control is achieved; continued for a period measured in a year or more To prevent relapse, which occurs most often during or after a reduction
7. Rehabilitation Physiotherapy, occupational therapy, speech and language therapy, neuropsychology From the acute admission onward, continuing for months after discharge To convert neurological recovery into function: a day, a conversation, a return to work

Three things about this order are worth stating plainly, because they are where practice varies most. Step 1 and step 2 overlap — aciclovir is not stopped before immunotherapy begins, and one is not a reason to delay the other. Step 3 is not deferred — a tumour is not a thing to be dealt with after the immunotherapy has finished, and delaying removal to "stabilise" the person is usually the wrong trade. And step 7 is not the last step: rehabilitation runs alongside everything from the acute phase, and stopping it at discharge is one of the commonest ways a good neurological recovery is wasted.

First-line immunotherapy

Three treatments make up first-line therapy, and they are chosen and combined according to severity, to the antibody where it is known, and to what the person can tolerate. All three are routinely available and all three work on the same principle: reduce the immune attack now, quickly, while the rest of the assessment completes.

  • High-dose corticosteroid — usually methylprednisolone given intravenously in pulses over several days, followed by an oral dose that is reduced gradually. It is fast and familiar. What families should know: mood, sleep and blood sugar can all be affected, appetite increases, and blood pressure and blood sugar are monitored while it is being given. A rise in agitation or sleeplessness in the first days is usually the steroid rather than the illness, and it is worth saying so before it is mistaken for deterioration.
  • Intravenous immunoglobulin — pooled antibody from donors, given over several days. It is used alone or with steroid, and it is often preferred where infection is still a live possibility or where steroid side effects are a particular problem. What families should know: it requires adequate hydration, it can cause headache, and very rarely it affects the kidneys or causes a clot — which is why it is given with observation and, in some people, more slowly.
  • Plasma exchange — the person's plasma is removed and replaced, physically clearing antibody and inflammatory proteins. It is the fastest of the three in principle, and it is used particularly where the illness is severe or where a cell-surface antibody is already known. What families should know: it needs a large-bore venous line, it can lower blood pressure and clotting factors during the exchange, and it is not available everywhere — which is a legitimate reason to start with steroid or immunoglobulin rather than to wait for it.

Combination rather than sequence. Where the illness is severe — the person is in intensive care, has seizures that will not stop, or has autonomic instability — first-line treatments are often given together rather than one after another, because waiting to see whether the first one worked is time the brain does not have. The choice between them is made by the treating team on the specifics of the case: the antibody where known, the severity, the person's other conditions, and what is available immediately.

What "response" looks like, and when. Improvement is not immediate and its absence in the first week is not failure. Consciousness and autonomic stability often settle first; seizures and movements take longer; behaviour and memory longer again. A defined reassessment point is set — typically after a course has completed rather than after a single dose — and the decision to move to second-line treatment is made there, on the documented trajectory rather than on day three.

Tumour removal: the step that changes the course

In the paraneoplastic forms of this illness, the tumour is not an incidental finding and it is not a separate problem to be dealt with later. It is the source of the immune stimulus, and removing it is the intervention most likely to change the trajectory — more reliably, in most reported experience, than any of the immunosuppressive drugs.

The mechanism is worth understanding, because it explains the treatment order. A tumour that happens to express the same protein as a nerve cell provokes an immune response against that protein. The response does not stay local: it crosses into the nervous system and attacks the same protein where it belongs. Suppressing the immune response without removing the tumour is therefore treating the consequence while the cause remains in place, which is why both are done and why the tumour is not deferred.

What this looks like in practice. An ovarian teratoma in a young woman with NMDA receptor encephalitis is removed once the person is stable enough for anaesthesia, and the immunotherapy continues around the surgery rather than instead of it. A thymoma is resected, and the immune disease is then treated on its own trajectory. A small cell lung cancer is treated oncologically, with the neurological immunotherapy running in parallel. In each case the sequencing is a joint decision between neurology, surgery and oncology rather than a fixed rule, and the commonest error is waiting too long.

What families ask about this, honestly. Finding a tumour is frightening, and it is frequently misread as things getting worse. It is usually the opposite: it gives the treatment a target and a mechanism, and in this illness it is often the better finding rather than the worse one. Where no tumour is found, treatment does not stop and the plan does not collapse — the tumour search is repeated according to the antibody group, and immunotherapy proceeds on the same basis. How the tumour link works is set out on the causes page, and how hard to look on the diagnosis page.

Second-line therapy and what follows

Second-line treatment is not a stronger version of first-line treatment; it works on a different part of the immune system. First-line therapy reduces the antibody and the inflammation that are present now. Second-line therapy reduces the cells that go on making the antibody, which is why it is used when first-line treatment has not brought the illness under control rather than alongside it from the start.

  • Rituximab — an antibody that depletes the B cells responsible for producing the antibody driving the disease. It is the most commonly used second-line agent, particularly in NMDA receptor disease, and it is given as a course with monitoring of blood counts and immunoglobulin levels afterwards. Because B-cell depletion lasts for months, the monitoring continues well past the last dose, and vaccination timing is planned around it.
  • Cyclophosphamide — a chemotherapy agent used in selected cases, usually where rituximab has not been sufficient or where the antibody and the clinical picture call for a T-cell-directed approach. It carries a larger burden: effects on fertility, on the bone marrow and on the bladder are real, and the decision to use it is made explicitly rather than by default, with those risks stated in advance.
  • Other approaches in refractory disease — including agents directed at the long-lived plasma cells that keep producing antibody, and, in carefully selected situations, participation in a clinical trial. These belong to a specialist setting and to a discussion that says plainly what is known and what is not.

The threshold for moving to second-line treatment is a judgement, not a rule. It is made at a defined reassessment, on the documented trajectory, taking into account severity, the antibody, and whether a tumour has been found and removed. Moving early is not a failure of the first treatment; moving late is the more common error. Conversely, not everyone needs it — a person who has responded well to first-line therapy with a cell-surface antibody and no tumour may never require it, and adding it anyway would only add risk.

What follows after control is achieved is maintenance: immunosuppression at a lower intensity, continued for a period measured in a year or more, and then reduced slowly with defined review points rather than stopped. The monitoring during this phase is not optional — blood counts, immunoglobulin levels where relevant, and a named route back if something changes. The maintenance and monitoring schedule is set out on the recovery page.

Treating the symptoms while the immunotherapy works

Immunotherapy takes days to weeks to change the course, and during that time the person is unwell from the symptoms rather than from the immune attack as an abstraction. Symptom treatment is not an adjunct to the real treatment — during the acute phase it is a large part of what keeps people safe.

  • Seizures. Antiseizure medicine is given and escalated as needed, including anaesthesia for seizures that will not stop. The caveat that matters: in several subtypes, including LGI1 disease, the seizures respond to immunotherapy far better than to antiseizure medicine, and escalating to a third or fourth drug without treating the immune disease is the wrong sequence.
  • Agitation, hallucinations and sleeplessness. Treated, because leaving them untreated is dangerous. But the choice is made carefully: certain antipsychotics can worsen autonomic instability here and can precipitate a reaction resembling neuroleptic malignant syndrome. The general practice is the lowest effective dose of a better-tolerated agent, with the reaction watched for; benzodiazepines are used for catatonia and severe agitation where appropriate; and sleep is treated as a clinical problem rather than a nuisance.
  • Autonomic instability. Blood pressure and heart rate are managed in a monitored setting, with medicines chosen for the direction of the swing rather than reflexively. Fever without a source is investigated rather than assumed to be the illness.
  • Breathing. Where the drive to breathe is affected, ventilatory support carries the person through the phase. It is a phase, not a verdict, and people come off ventilation as the inflammation is controlled.
  • Swallowing and nutrition. Assessed formally rather than inferred from the cough at mealtimes. A temporary feeding tube is sometimes the right decision, and it is reversible.
  • The immobility complications. Clot prevention, pressure care, chest physiotherapy, and contracture prevention — the ordinary business of intensive care, which in this illness is the difference between a neurological recovery and a complicated one.
  • Medicines that make it worse. A medication review, specifically for anticholinergic and sedative load, which can add confusion on top of encephalitis and is one of the few things that can be improved within a day.

And one thing that is often omitted: the person inside this illness is usually aware of far more than their stillness suggests. Speaking to them, explaining the plan, and keeping one familiar person present are not niceties. People who have been through the severe phase describe being treated as absent while fully present as one of the worst parts of it.

Recovery: months, not weeks

This is the part families are least prepared for, and the part where the most unnecessary despair happens. The immune attack can be interrupted in days. The brain's recovery from it takes months, and in some respects longer.

The order of recovery is usually the reverse of the order of onset. Consciousness and autonomic stability return first, then movement, then behaviour, and last — often much last — the memory, attention and executive function that make independence possible. Fatigue, sleep and mood typically trail behind everything else. A family may see the person "come back" while the person themselves is still unable to hold a plan in mind or to work a full day, and that gap is a recognised part of the illness rather than a sign that something new has gone wrong.

The curve is not smooth. Weeks of apparent plateau followed by a clear step forward is the normal shape. A temporary worsening while steroids are being reduced is common and is not the same as treatment failure. Decisions are made on the trend across weeks, not on a single day, and the single most useful thing a family can keep is the simple daily record started in the acute phase — consciousness, seizures, movements, and the specific functions that matter to this person.

What nobody can promise. Not a cure, and not a return to exactly the previous level. What can be said honestly: improvement continues over many months, a substantial proportion of people recover well enough to return to an independent life, and a proportion are left with residual difficulty — most often in memory, attention, stamina, sleep and mood. The things that influence where a person lands are the severity of the acute phase, how early treatment started, whether a tumour was found and removed, whether relapse occurred, and how consistently rehabilitation was pursued.

Rehabilitation is the treatment of this phase. Physiotherapy for mobility and deconditioning, occupational therapy for the practical business of a day, speech and language therapy for swallowing and communication, and neuropsychology for the cognitive and emotional consequences — with vocational planning for the return to work, which is often the last and hardest step and is best planned rather than attempted. The recovery page sets out how this phase is structured over the following year.

Relapse and what the plan is for it

Relapse — the return of symptoms after a period of clear improvement — occurs in a minority of people, and it is the reason the maintenance phase exists. It is also, importantly, usually treatable, which is the sentence families most need to hear when it happens.

When it happens. Most often during or after a reduction of immunosuppression, which is why the taper is planned with defined review points rather than improvised. It can also happen after a period of stability with no change in treatment, and occasionally the second episode looks different from the first — more memory and less behaviour, or the reverse.

What it is not. It is not proof that the original treatment failed, and it is not a sign that the illness has become untreatable. It is information: the immune response was suppressed rather than extinguished, and the suppression needs to be at a different level or for a different duration. Most relapses respond to re-escalation, and the plan is adjusted rather than abandoned.

What a relapse plan contains, in writing. The specific changes that count as a relapse for this person — not a generic list, but the three or four things that would actually be noticed first in them. Whom to call, and by when. What happens if it occurs out of hours or while travelling. And what is not a relapse: an intercurrent infection, a medicine change, a bad week of sleep, or the ordinary fluctuations that continue during recovery. Distinguishing the two is the hardest part for families, and it is worth writing down rather than deciding in the moment.

What else is watched. Where an intracellular antibody was identified, the tumour search is repeated at intervals over the following years, because a relapse can occasionally be the first indication of a tumour that was not present on the first screen. And where B-cell-depleting therapy has been used, blood counts and immunoglobulin levels are monitored on a schedule, because the effects of the treatment last longer than the treatment itself.

Frequently Asked Questions

How long does the immunotherapy continue, and why so long?

Longer than families expect, for a specific reason. First-line immunotherapy is given as pulses or a defined course; the part that lasts is maintenance, continued for a year or more and reduced slowly rather than stopped. The reason is relapse: a minority have the illness return, most often during or after a reduction. So the taper is planned, with review points, a documented relapse plan and someone named to call. Its length is set by the subtype, the severity, whether a tumour was found, and the response.

If a tumour is found, does removing it replace the immunotherapy?

No. Both are needed and they work on different halves of the problem. Removing the tumour takes away the source of the immune stimulus, and in paraneoplastic cases it is the step most likely to change the course; but the response it started does not switch off with it, which is why immunotherapy continues alongside. Outcomes are better where a tumour is found and treated — a statement about direction, not a promise, and not a verdict on those without one.

Why is psychiatric medicine being given, and is it safe here?

Because severe agitation, hallucinations and sleeplessness are dangerous in themselves, and leaving them untreated is not neutral. But the choice and dose matter more than usual: antipsychotics can worsen the autonomic instability seen here and can precipitate a reaction resembling neuroleptic malignant syndrome — stiffness, fever, rising muscle enzymes. The usual practice is the lowest effective dose of a better-tolerated agent, watching for the reaction, with benzodiazepines for catatonia. A sharp deterioration after starting one is a reason to reassess, not to increase the dose.

When does rehabilitation start, and does it change the outcome?

During the acute admission, not after it. Physiotherapy for mobility and the deconditioning a month in bed produces; speech therapy for swallowing and communication; occupational therapy for washing, dressing and eating; neuropsychology for the memory and attention problems that improve last. It changes the outcome in the only sense that matters to the person: neurological recovery on a chart is one thing, and managing a day, a conversation and eventually a job is another.

Get the treatment sequence reviewed against the subtype

Send the timeline, the antibody report with the fluid on which it was run, the discharge summaries, a list of every immunotherapy given with dates and doses, the tumour screening done so far, and a short note on where the person is now compared with a month ago. Our team will return a written opinion on whether the sequence so far matches the subtype and severity, what the next line should be and when, and what the monitoring and relapse plan should contain.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*